StemCure

04/18/2023

https://igg.me/at/stemcure/x/31513338 #/

Preserving your cells today may offer you access to anti-aging medical therapies in the future | Check out 'Cryopreservation of young, healthy human cells' on Indiegogo.

04/18/2023

Preserving your cells today may offer you access to anti-aging medical therapies in the future | Check out 'Cryopreservation of young, healthy human cells' on Indiegogo.

03/19/2023

10/03/2016

StemCure is the only Personal Tissue Bank, which offers anyone the ability to save a sample of their cells today for future use as they grow older. Our clients’ personal cell archive may offer them the best access to emerging regenerative and anti-aging medical therapies in the future.
Cryopreserving a small piece of skin tissue today can significantly change your life in the future. The sooner you preserve your tissue, the younger you are, the higher the chance for success!
For more details visit website at: https://www.stemcure.com/

09/21/2016

Lund University stem cell researcher awarded Fernström prize for study on repairing damaged brain.

Medical Science News, September 21, 2016.

Is it possible to convert a patient’s own skin cells into functioning nerve cells? Or insert healthy genes to reprogram the cells of a damaged brain? Stem cell researcher Malin Parmar at Lund University in Sweden is studying these types of issues, in close collaboration with clinical researchers. She is now awarded a prize of SEK 100 000 from the Eric K. Fernström Foundation for her work.
Every year, the Fernström Foundation presents one large Nordic prize (which will be announced later in September) as well as local prizes to researchers at the six faculties of medicine in Sweden. Malin Parmar has received Lund University’s local prize for her studies on how to repair a brain that has suffered damage due to, for instance, Parkinson’s disease, with the help of advanced methods.
Her work involves three different aspects of research:
1. Making stem cells develop into dopamine-producing nerve cells, which can be inserted into the brains of patients who suffer from Parkinson’s, and thus have low levels of the signal substance dopamine
2. Reprogramming skin cells directly into dopamine cells, without having to go through a stem cell stage
3. Inserting genes into the brain to perform such reprogramming on the spot, and making, for example, glial cells (a type of connective tissue) convert into dopamine cells.
“I believe in all three methods. They each have their advantages and disadvantages, and very different time perspectives”, she says.
The first method will also be the first to be tested, in which stem cells, that have been cultivated in a lab, will be made to transform into dopamine cells to be transplanted into the patient’s brain. Trials with human patients are expected to begin within two years.
A characteristic feature of stem cells is that they love to divide and create new cells. This is both an advantage and a disadvantage in this context. The advantage is that it is easy to obtain large quantities of cells to transplant. The disadvantage is that the division must be monitored carefully, so as to not have the process take off in an uncontrolled manner, similar to what happens in cancer.

http://www.news-medical.net/news/20160921/Lund-University-stem-cell-researcher-awarded-Fernstrom-prize-for-study-on-repairing-damaged-brain.aspx

Is it possible to convert a patient’s own skin cells into functioning nerve cells? Or insert healthy genes to reprogram the cells of a damaged brain? Stem cell researcher Malin Parmar at Lund University in Sweden is studying these types of issues, in close collaboration with clinical researchers.

09/21/2016

Experimental stem cell therapy helps restore paralyzed man’s movement.

Fox News, September 12, 2016.

When Kris Boesen’s car fishtailed on a wet road, hitting a tree and slamming into a telephone poll, the 21-year-old never thought he would walk again. But results from an early-stage clinical trial using stem cells to restore movement have given the 21-year-old promise that his spinal cord injury may one day be reversed, Fox 5 Atlanta reported.
Boesen, of Bakersfield, California, qualified for the study at the Keck Medical Center of the University of Southern California (USC).
“He was extremely excited about having an opportunity to try to do something—to get better than he was at that point,” Boesen’s father, Rodney Boesen, told the news station.
Doctors told the young man that he’d likely never have movement or sensation below his neck, but the trial aimed to improve those functions.
In early April— within two weeks to 30 day of Boesen’s injury— neurosurgeon Charles Liu and his team injected 10 million stem cells, called AST-OPC1 cells, directly into his cervical spinal cord, Fox 5 Atlanta reported. Within two weeks, the effects of his accident began to improve.
“Patients who suffer these disabilities want more than anything else to do something for themselves,” says Dr. Liu, director of the USC Neurorestoration Center, told the news station. “They want to be more independent, less dependent. It makes all of us appreciate how important it is that we can do these things.”

http://www.foxnews.com/health/2016/09/12/experimental-stem-cell-therapy-helps-restore-paralyzed-mans-movement.html

09/21/2016

Stem cell therapy restores arm, hand movement for paralyzed man
Written by Honor Whiteman,

Medical News Today, September 8, 2016
A 21-year-old man left paralyzed after a spinal cord injury has regained the use of his arms and hands, thanks to an experimental stem cell treatment performed by researchers from the Keck Medical Center at the University of Southern California.
In March of this year, Kristopher (Kris) Boesen, from Bakersfield, CA, was involved in a car accident, in which he suffered severe trauma to his cervical spine that left him paralyzed from the neck down and unable to breathe without assistance.
Doctors told Kris that he might never regain the use of his limbs; current surgical procedures for spinal cord injury focus on stabilizing the spine to prevent further damage, but they rarely improve movement and sensation.
Kris then learned of a clinical trial – led by Dr. Edward D. Wirth III, chief medical director of Asterias Biotherapeutics – looking to enroll patients with spinal cord injury.
The ongoing trial is testing a novel therapy involving injections of AST-OPC1 – an agent consisting of oligodendrocyte progenitor cells (OPCs) that derive from embryonic stem cells. OPCs are the myelin-forming cells of the brain and spinal cord that help nerve cells to function.
According to Asterias Biotherapeutics – the developer of AST-OPC1 – preclinical trials of the agent in models of spinal cord injury have shown it leads to “reduction of the size of the injury cavity, restoration of the protective ‘myelin’ coating on nerve cells, production of factors that stimulate nerve cell growth, and recruitment of blood vessels to deliver oxygen and nutrients to the site.”
In order to take part in the trial – named “SCiStar” – patients need to be able to breathe without the help of a ventilator. Though it normally takes 3 weeks to wean a patient off assisted breathing, with the help of a dedicated respiratory team, Kris managed it in 5 days.
After further tests, he was confirmed as being eligible to take

http://www.medicalnewstoday.com/articles/312796.php

A man left paralyzed from a spinal cord injury has regained movement in his arms and hands as a result of a novel stem cell treatment.

09/21/2016

Functional human tissue-engineered liver generated from stem and progenitor cells.

Medical Xpress, Aug 30, 2016.

A research team led by investigators at The Saban Research Institute of Children’s Hospital Los Angeles has generated functional human and mouse tissue-engineered liver from adult stem and progenitor cells. Tissue-engineered Liver (TELi) was found to contain normal structural components such as hepatocytes, bile ducts and blood vessels. The study has been published online in the journal Stem Cells Translational Medicine.
Liver disease affects pediatric and adult patients, impacting one in ten people in the United States. Liver transplantation is the only effective treatment for end-stage liver disease, but scarcity of available organs and the need for lifelong immunosuppressive medication make this treatment challenging.
Alternate approaches that have been investigated include significant limitations. For example, conventional liver cell transplantation requires scarce donor liver and a perfusion protocol that wastes many cells. This type of cell transplant typically lasts less than one year, with most patients ultimately requiring a liver transplant. Human-induced pluripotent stem (iPS) cells are another possibility but, so far, iPS cells have remained immature rather than developing into functional and proliferative liver cells, called hepatocytes. There continues to be a need for a durable treatment, particularly one that could eliminate the need for immunosuppression.
“Based on the success in my lab generating tissue-engineered intestine and other cell types, we hypothesized that by modifying the protocol used to generate intestine, we would be able to develop liver organoid units that could generate functional tissue-engineered liver when transplanted,” said Tracy C. Grikscheit, MD, a pediatric surgeon and researcher at The Saban Research Institute of CHLA and co-principal investigator on the study. Grikscheit is also a tenured associate professor of Surgery at the Keck School of Medicine of USC.
The research team generated liver organoid units (LOU) from human and mouse liver and implanted both varieties of LOU into murine models. Tissue-engineered liver developed from the human and mouse LOU, with key cell types required for hepatic function including patent bile ducts and blood vessels, hepatocytes, stellate cells and endothelial cells. However, the cellular organization differed from native liver tissue.
Human albumin, the main type of protein in the blood, was detected in the host mouse serum, indicating in vivo secretory function from the human-derived tissue-engineered liver. In a mouse model of liver failure, tissue-engineered liver was able to provide some hepatic function. In addition, the hepatocytes proliferated in the tissue-engineered liver.
“A cellular therapy for liver disease would be a game-changer for many patients, particularly children with metabolic disorders,” said Kasper S. Wang, MD, a pediatric surgeon and researcher at The Saban Research Institute of CHLA and co-principal investigator on the study. “By demonstrating the ability to generate hepatocytes comparable to those in native liver, and to show that these cells are functional and proliferative, we’ve moved one step closer to that goal.” Wang is also associate professor of Surgery at the Keck School of Medicine of USC and a principal investigator for the national consortium, the Childhood Liver Disease Research and Educational Network.

http://medicalxpress.com/news/2016-08-functional-human-tissue-engineered-liver-stem.html

A research team led by investigators at The Saban Research Institute of Children's Hospital Los Angeles has generated functional human and mouse tissue-engineered liver from adult stem and progenitor cells. Tissue-engineered Liver (TELi) was found to contain normal structural components such as hepa...